AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 Lausanne, Switzerland, May 28, 2023 “ AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company...
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease Takeda to receive exclusive option to license global rights...
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for...
AC Immune Reports Full Year 2023 Financial Results
AC Immune Announces Upcoming Presentations at AD/PD 2024 Multiple presentations at the International Conference on Alzheimer™s and Parkinson™s Diseases (AD/PD 2024)Andrea Pfeifer, Ph.D., CEO to...
AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company™s strategy is focused on advancing the Phase 2 development of its three active immunotherapiesActive immunotherapy now...
Genentech is walking away from an 18-year relationship with AC Immune, handing back global rights to a pair of Alzheimer’s disease drug candidates after suffering a series of setbacks in the clinic.
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases ABATE Phase 1b/2 AD trial of ACI-24.060 completed enrollment of cohorts 1 and 2 and...